Silvercrest Asset Management’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$19.7M Buy
461,588
+395,123
+594% +$21.5M 0.13% 212
2026
Q1
$4.17M Sell
66,465
-2,549
-4% -$204K 0.03% 447
2025
Q4
$6.58M Sell
69,014
-728
-1% -$71.4K 0.05% 397
2025
Q3
$6.81M Buy
69,742
+1,486
+2% +$154K 0.05% 382
2025
Q2
$7.33M Buy
68,256
+2,635
+4% +$267K 0.05% 372
2025
Q1
$6.62M Sell
65,621
-2,674
-4% -$269K 0.05% 362
2024
Q4
$6.1M Buy
68,295
+4,095
+6% +$360K 0.04% 382
2024
Q3
$5.38M Buy
64,200
+7,259
+13% +$572K 0.04% 375
2024
Q2
$4.39M Buy
56,941
+6,133
+12% +$449K 0.03% 422
2024
Q1
$3.48M Buy
50,808
+11,138
+28% +$716K 0.02% 441
2023
Q4
$2.29M Buy
39,670
+32,733
+472% +$1.75M 0.02% 476
2023
Q3
$366K Hold
6,937
﹤0.01% 721
2023
Q2
$375K Sell
6,937
-13
-0.2% -$679 ﹤0.01% 715
2023
Q1
$348K Hold
6,950
﹤0.01% 698
2022
Q4
$322K Sell
6,950
-11
-0.2% -$476 ﹤0.01% 697
2022
Q3
$270K Sell
6,961
-2,000
-22% -$80.2K ﹤0.01% 717
2022
Q2
$334K Sell
8,961
-409
-4% -$16.6K ﹤0.01% 702
2022
Q1
$415K Buy
9,370
+11
+0.1% +$477 ﹤0.01% 712
2021
Q4
$398K Sell
9,359
-3,288
-26% -$138K ﹤0.01% 702
2021
Q3
$549K Sell
12,647
-573
-4% -$25.4K ﹤0.01% 660
2021
Q2
$565K Buy
13,220
+320
+2% +$13.5K ﹤0.01% 647
2021
Q1
$499K Sell
12,900
-8,625
-40% -$326K ﹤0.01% 669
2020
Q4
$774K Sell
21,525
-1,015
-5% -$36.6K 0.01% 571
2020
Q3
$861K Hold
22,540
0.01% 534
2020
Q2
$791K Buy
22,540
+4,000
+22% +$144K 0.01% 543
2020
Q1
$605K Buy
18,540
+8,300
+81% +$324K 0.01% 550
2019
Q4
$463K Hold
10,240
﹤0.01% 607
2019
Q3
$417K Buy
10,240
+790
+8% +$33.5K ﹤0.01% 602
2019
Q2
$406K Sell
9,450
-170
-2% -$6.54K ﹤0.01% 457
2019
Q1
$369K Hold
9,620
﹤0.01% 455
2018
Q4
$340K Hold
9,620
﹤0.01% 421
2018
Q3
$370K Sell
9,620
-198
-2% -$6.92K ﹤0.01% 434
2018
Q2
$321K Sell
9,818
-25
-0.3% -$754 ﹤0.01% 450
2018
Q1
$269K Hold
9,843
﹤0.01% 489
2017
Q4
$244K Sell
9,843
-2,464
-20% -$68K ﹤0.01% 513
2017
Q3
$359K Sell
12,307
-36
-0.3% -$994 ﹤0.01% 448
2017
Q2
$342K Buy
12,343
+2,400
+24% +$63.7K ﹤0.01% 442
2017
Q1
$247K Sell
9,943
-35
-0.4% -$851 ﹤0.01% 518
2016
Q4
$216K Sell
9,978
-265
-3% -$5.78K ﹤0.01% 543
2016
Q3
$244K Buy
10,243
+60
+0.6% +$1.43K ﹤0.01% 492
2016
Q2
$238K Sell
10,183
-32
-0.3% -$692 ﹤0.01% 500
2016
Q1
$192K Sell
10,215
-1,525
-13% -$26.8K ﹤0.01% 520
2015
Q4
$216K Hold
11,740
﹤0.01% 526
2015
Q3
$193K Hold
11,740
﹤0.01% 460
2015
Q2
$208K Buy
+11,740
New +$210K ﹤0.01% 487
2015
Q1
Sell
-11,415
Closed -$151K 489
2014
Q4
$151K Buy
+11,415
New +$146K ﹤0.01% 463
2014
Q3
Sell
-14,765
Closed -$189K 463
2014
Q2
$189K Buy
+14,765
New +$192K ﹤0.01% 457

Other funds holding BSX

Silvercrest Asset Management's BSX Position: Q2 2026 in Review

Silvercrest Asset Management increased its Boston Scientific (BSX) stake by 594% in Q2 2026, buying an estimated $21.5M and bringing the position to 461,588 shares worth $19.7M. The position accounts for 0.13% of the portfolio, ranked #212.

Silvercrest Asset Management first reported a position in BSX in Q2 2014 and has held it in 47 quarters since. 1,470 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Silvercrest Asset Management held 461,588 shares of Boston Scientific worth $19.7M as of Q2 2026.
  • Silvercrest Asset Management bought 395,123 Boston Scientific shares in Q2 2026, an estimated $21.5M.
  • Boston Scientific made up 0.13% of Silvercrest Asset Management's portfolio in Q2 2026, its #212 holding.
  • Silvercrest Asset Management first reported a position in Boston Scientific in Q2 2014 and has held it in 47 quarters since.
  • 1,470 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Silvercrest Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.